Kevin Antoine Brown
Kevin Antoine Brown is a Canadian infectious disease epidemiologist and health services researcher at Public Health Ontario and the University of Toronto.
He is notable during the COVID-19 pandemic due to his role on the Ontario COVID-19 Science Advisory Table.
Education
Brown received his PhD in Epidemiology from the University of Toronto and his MSc in Biostatistics from the University of North Carolina.
Career and Affiliations
ICES
Brown is an adjunct scientist at the Institute for Clinical Evaluative Sciences (ICES).
Research
He studies healthcare-associated infections and antimicrobial resistance, with a specialty in Clostridiodes difficile. His research has focused on creating reproducible indexes of antibiotic risk, understanding the role of built environment in infectious disease transmission, and documenting geographic variation in diagnosis of infections, prescribing of antibiotics, and outcomes.1)
Funding
Brown has received research funding from the Canadian Institutes of Health Research (CIHR).2) 3)
He also received funding for COVID-19 research from the COVID-19 Emergency Response Fund from the Ottawa Hospital.4)
The Ottawa Hospital has received funding for research from Pfizer for research on drugs for advanced lung cancer,5) kidney transplant patients6) 7) and blood clots in cancer patients.8) 9)
1)
About Us. Ontario COVID-19 Science Advisory Table. Retrieved March 11, 2022, from https://covid19-sciencetable.ca/about/#brown-kevin-antoine
2)
Brown, K. A. (2021). Declaration of Interest. Ontario COVID-19 Science Advisory Table. https://web.archive.org/web/20220108230040/https://covid19-sciencetable.ca/wp-content/uploads/2021/02/Declaration-of-Interest_Congregate-Care-Setting-Working-Group_Kevin-Brown_20211014.pdf
3)
Brown, K. A. (2021). Declaration of Interest. Ontario COVID-19 Science Advisory Table. https://covid19-sciencetable.ca/wp-content/uploads/2021/02/Declaration-of-Interest_Congregate-Care-Setting-Working-Group_Kevin-Brown.pdf
4)
MacFadden, D. R., Brown, K., Buchan, S. A., Chung, H., Kozak, R., Kwong, J. C., Manuel, D., Mubareka, S., & Daneman, N. (2022). Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications. Open Forum Infectious Diseases. https://doi.org/10.1093/ofid/ofac156
5)
Early phase clinical trials shows promising results in advanced lung cancer. (2011, October 12). Ottawa Hospital Research Institute. https://archive.ph/QMO7q
6)
Knoll, G. A., Kokolo, M. B., Mallick, R., Beck, A., Buenaventura, C. D., Ducharme, R., Barsoum, R., Bernasconi, C., Blydt-Hansen, T. D., Ekberg, H., Felipe, C. R., Firth, J., Gallon, L., Gelens, M., Glotz, D., Gossmann, J., Guba, M., Morsy, A. A., Salgo, R., & Scheuermann, E. H. (2014). Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ, 349(nov24 1), g6679–g6679. https://doi.org/10.1136/bmj.g6679
7)
Ganton, J. (2015, October 22). Drugs commonly used in kidney transplant patients not as effective as previously thought. Ottawa Hospital Research Institute. https://archive.ph/SGtWQ
8)
Ganton, J., & Pulkinghorn, I. M. (2018, December 4). Drug dramatically reduces risk of dangerous blood clots in cancer patients. Ottawa Hospital Research Institute. https://archive.ph/n6N5h
9)
Carrier, M., Abou-Nassar, K., Mallick, R., Tagalakis, V., Shivakumar, S., Schattner, A., Kuruvilla, P., Hill, D., Spadafora, S., Marquis, K., Trinkaus, M., Tomiak, A., Lee, A. Y. Y., Gross, P. L., Lazo-Langner, A., El-Maraghi, R., Goss, G., Le Gal, G., Stewart, D., & Ramsay, T. (2019). Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. The New England Journal of Medicine, 380(8), 711–719. https://doi.org/10.1056/NEJMoa1814468